



## **MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference**

November 18, 2025

CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present and participate in the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4.

### **37th Annual Piper Sandler Healthcare Conference**

Date: Tuesday, December 2, 2025  
Format: Fireside chat and 1x1 meetings  
Time: 4:00 p.m. – 4:25 p.m. ET  
Location: New York, NY

The live webcast can be accessed in the events section of the MBX Biosciences website at <https://investors.mbxbio.com/news-events/events>. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company's website for approximately 90 days.

### **About MBX Biosciences**

MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; imapexotide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at <https://mbxbio.com/> and follow it on [LinkedIn](#).

### **Media Contact:**

Cassidy McClain  
Inizio Evoke Comms  
[cassidy.mcclain@inizioevoked.com](mailto:cassidy.mcclain@inizioevoked.com)  
(619) 694-6291

### **Investor Contact:**

Jim DeNike  
MBX Biosciences  
[jdenike@mbxbio.com](mailto:jdenike@mbxbio.com)